Hemispherx stock: buy or sell?

HEB stock price: $4.37 1.16% At close on June 26th, 2019

Updated on:
June 26th, 2019


After boosting an exceptional 7.87% yesterday, Hemispherx closed today at $4.37 and appreciated a good 1.16%. On June 19th HEB collapsed a dreadful -6.22%.

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States.

Should I buy Hemispherx stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Hemispherx stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Hemispherx BioPharma stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't find any rating for HEB stock for the last month.

Hemispherx stock analysis

Daily outlook

After boosting an exceptional 7.87% yesterday, Hemispherx closed today at $4.37 and appreciated a good 1.16%.

After boosting an exceptional 7.87% yesterday, Hemispherx closed today at $4.37 and appreciated a good 1.16%.

HEB stock chart (daily)

Weekly outlook

After sliding a bloodcurdling -22.12% in a week last week, Hemispherx closed this week at $4.37 and boosted an impressive 5.05%. By mid June HEB climbed a super good 13.39% in just one week.

Since price and 20-weeks moving average lines crossed down by mid February, HEB fell $-5.75 per share (-56.82%).

HEB stock chart (weekly)

Hemispherx stock price history

Hemispherx stock went public on July 22nd, 1996 with a price of $27.001. Since then, HEB stock declined a -83.80%, with a yearly average of -3.80%.

1: Adjusted price after possible price splits or reverse-splits.

Hemispherx stock historical price chart

HEB stock reached 52-week highs on April at $14.96, and all-time highs 2004-04-29 with a price of 2851.2.

Hemispherx stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we have not found any price prediction for Hemispherx stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

After presenting its last earnings report on April, Hemispherx plunged a frightening -37.93%. Unfortunately, reported EPS is not yet available in our database.
HEB earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual turnover report draw a hair-raising decrease of -16.02% to $0.37 M dollars. Similarly, its income margin (compared to sales) plunged to -2,673.84%, that is $-9.81 million.

HEB annual Sales and Income evolution
2012$0.21 M-$-17.35 M-8145.5%-
2013$0.15 M-29.58%$-16.23 M-10820.0%-6.46%
2014$0.20 M31.33%$-17.45 M-8857.9%7.52%
2015$0.13 M-32.49%$-15.23 M-11451.1%-12.72%
2016$0.09 M-30.83%$-7.50 M-8154.3%-50.74%
2017$0.44 M375.00%$-8.26 M-1889.9%10.09%
2018$0.37 M-16.02%$-9.81 M-2673.8%18.82%

Quarterly financial results

Hemispherx BioPharma reported $0.24 million in sales for 2018-Q4, a 531.58% improvement compared to previous quarter. Reported quarter income marked $-1.61 million with a profit margin of -669.58%. Profit margin skyrocketed a 7,430.42% compared to previous quarter when profit margin was -8,100.00%. When comparing turnover to same quarter last year, Hemispherx sales marked an outstanding gain and boosted a 380.00%. Looking back to recent quarterly results, Hemispherx BioPharma posted 2 positive quarters in a row.
HEB quarterly Sales and Income evolution
2017-Q1$0.08 M-$-2.82 M-3357.1%-
2017-Q2$0.21 M153.57%$-2.19 M-1028.2%-22.34%
2017-Q3$0.09 M-57.75%$-1.25 M-1391.1%-42.83%
2017-Q4$0.05 M-44.44%$-1.99 M-3986.0%59.19%
2018-Q1$0.06 M12.00%$-2.71 M-4844.6%36.13%
2018-Q2$0.03 M-41.07%$-2.42 M-7318.2%-10.98%
2018-Q3$0.04 M15.15%$-3.08 M-8100.0%27.45%
2018-Q4$0.24 M531.58%$-1.61 M-669.6%-47.79%

Hemispherx ownership

When you are planning to invest in a stock, it's worth to check its ownership structure.

Hemispherx shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 12.78% of all shares.

In case of Hemispherx stock, 6.09% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for HEB stock account 0.00%, no big difference from last month.

For a better understanding, the next table shows ownership data compared to other related companies:

Market cap$423.1 M$52.0 B$41.1 B$84.7 B$197.5 B
Total shares96.8 M1,270.0 M510.2 M1,270.0 M4,920.0 M
Float shares1.8 M2,620.0 M509.5 M1,270.0 M2,440.0 M
  - Institutional holdings (%)6.1%19.4%88.2%82.6%11.0%
  - Insider holdings (%)12.8%0.0%0.1%0.7%0.0%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Hemispherx summary

Wednesday, June 26th, 2019
Day range$4.20 - $4.67
Previous close$4.32
Session gain1.16%
Average true range$0.91
50d mov avg$5.89
100d mov avg$7.05
200d mov avg$8.27
Daily patternlt03a
Weekly pattern lb06a

Hemispherx performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We picked Astrazeneca, Baxter International, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer and Sarepta Therapeutics as the bechmarking frame for Hemispherx BioPharma stock.
HEBHemispherx BioPha...-37.93%-47.73%-68.96%
BAXBaxter Internatio...-0.57%24.30%10.36%
GILDGilead Sciences3.54%9.83%-2.50%
SRPTSarepta Therapeut...7.68%18.99%-2.91%

Hemispherx competitors

One check before trading any stock is to have a look a list of its competitors, in this case for Hemispherx. We chose 7 companies as Hemispherx competitors as they are in the same industry or have similar market objectives.